MassDevice.com +5 | The top 5 medtech stories for April 25, 2016

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Questions surface about Palmaz Scientific’s fundraising Palmaz Scientific, which filed for Chapter 11 bankruptcy protection last month, is reportedly embroiled in a dispute with Jefferies &Co. over its claim that the prominent investment bank was the placement agent for a funding round in 2012 and 2013. Co-founded by coronary stent pioneer Dr. Julio Palmaz in 2008, the San Antonio, Texas-based company tapped Jefferies for a $7.5 million round in 2010, according to the San Antonio Express-News. But despite the fact that the Wall Street firm severed its ties with Palmaz Scientific in 2011, according to the newspaper, the medical device company continued to list Jefferies as the placement agent for another 2 years in marketing materials. Read more 4. FDA grants IDE to NovoCure for phase II Optune trial NovoCure said today that Radiation Therapy Oncology Group Foundation won FDA investigational device exemption to conduct a Phase II pilot test of NovoCure’s Optune in conjunction with bevacizumab to treat bevacizumab-refractory recurrent glioblastoma. The Optune...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 5 Source Type: news

Related Links:

Abstract Osteosarcoma is the most frequent and intractable malignancy of the bone in children and young adults. Surgical operation requires extensive excision of the cancer tissue and neighboring normal tissues. In addition, anticancer drugs and radiation therapy are thought to be almost ineffective. Glucose-regulated protein 78 (GRP78), a cell-protective endoplasmic reticulum (ER) chaperone protein, is one of the most promising anticancer targets for osteosarcoma. Here, by analyzing the molecular mechanisms of kuanoniamine C, we report that kuanoniamine C suppresses GRP78 expression via GRP78 mRNA degradation in ...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Elevated LDH, B symptoms, advanced stage and failure to achieve complete response after initial treatment are clinical variables associated with shorter progression ‐free survival (PFS) in pulmonary marginal zone lymphoma (PMZL). Multifocal lung disease, extrapulmonary MZL and cavitary lesions on computed tomography scans have been identified as radiologic features associated with shorter PFS. Radiation therapy and surgery are potentially curative strategies in PMZL. AbstractPulmonary marginal zone lymphoma (PMZL) is the most common non ‐Hodgkin lymphoma affecting the lung. PMZL is usually an indolent disease. Clinical...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Condition:   Prostate Cancer Interventions:   Drug: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC;   Radiation: Stereotactic Body Radiation Therapy (SBRT) Sponsors:   Weill Medical College of Cornell University;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 23 May 2020Source: Practical Radiation OncologyAuthor(s): Roman O. Kowalchuk, Michael R. Waters, K. Martin Richardson, Kelly M. Spencer, James M. Larner, C.R. Kersh
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Semin Respir Crit Care Med 2020; 41: 360-368 DOI: 10.1055/s-0039-3399578Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer and the leading cause of cancer-related death. Although durable local control rates are high after surgical resection or definitive radiotherapy for early-stage disease, a substantial proportion of these patients eventually experience regional and/or distant failure and succumb to their metastatic disease. The discovery of immunotherapeutics and targeted biologics has revolutionized the treatment of locally advanced and metastatic disease, improving progression-free and overal...
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Review Article Source Type: research
Semin Respir Crit Care Med 2020; 41: 435-446 DOI: 10.1055/s-0039-1700566Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by rapid growth and early spread. It is a highly lethal disease that typically is diagnosed at a late stage. Surgery plays a very small role in this cancer, and management typically involves chemotherapy, delivered with thoracic radiation in early-stage disease. Platinum-based chemotherapy is initially very effective, inducing rapid and often deep responses. These responses, though, are transient, and upon relapse, SCLC is highly refractory to therapy. Immunotherapy has...
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Review Article Source Type: research
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionAfter great improvements in rectal cancer treatment, late gastrointestinal toxicity after radiotherapy is experienced less frequent and less severe; however, it remains a great concern associated with worse quality of life.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
The use of a specific treatment technique in radiation therapy is mainly motivated by the achievable dose conformity to the target and the overall integral dose. Proton therapy offers a highly conformal and comprehensive treatment option with a lower integral dose (reduced low-dose bath) to organs at risk (OARs). Consequently, given the proximity of cardiopulmonary structures, proton therapy has been discussed as a treatment alternative for breast cancer patients [1 –3]. Treatment planning studies, comparing 3DCRT, IMRT, and proton therapy when irradiating the breast and regional nodes showed advantages of using prot...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Cayenne | Electronic Health Records (EHR) | Funding | Fundraising | Grants | Health | Marketing | Medical Devices | Mergers and Aquisitions | Radiation Therapy